The revenue for Endoxifen is expected to reach an annual total of $58 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Endoxifen Overview
Endoxifen is under development for the treatment of HER2 negative breast cancer, mammographic breast density for women and breast cancer for men, recurrent ovarian cancer. It is administered through oral and topical route. The drug candidate is an active metabolite of tamoxifen. It acts by targeting estrogen receptor.
It was also under development for gynecomastia.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Atossa Therapeutics Overview
Atossa Therapeutics (Atossa), formerly Atossa Genetics, is a clinical-stage biopharmaceutical company. It develops proprietary therapeutics and delivery methods for breast cancer and other breast conditions. The company’s pipeline pharmaceutical programs include endoxifen, an active metabolite of tamoxifen, used for the treatment of breast density and other breast health conditions. Atossa develops patented microcatheter technology to deliver fulvestrant as a potential treatment of ductal carcinoma through the nipple to site of early breast cancer. The company uses its proprietary intraductal microcatheter technology to deliver CAR-T cells into the ducts of the breast for the treatment of breast cancer. The company operates presence in Australia, the US and the UK. Atossa is headquartered in Seattle, Washington, the US.
The operating loss of the company was US$27.7 million in FY2022, compared to an operating loss of US$20.5 million in FY2021. The net loss of the company was US$27 million in FY2022, compared to a net loss of US$20.6 million in FY2021.
For a complete picture of Endoxifen’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
